Early data whet appetites ahead of the big event for one of the few remaining antiviral hopes in Covid-19.
New findings for IL-6 blockade in the Recovery trial finally confirm a signal. Can pending pandemic readouts for other mechanisms do the same?
Outside of vaccines and antibodies, few experimental agents have made it into large, robust clinical trials.
Encouraging early data in inflammatory bowel disease have given Abivax a second avenue to pursue with its lead HIV asset.